Boston Scientific stock dipped Wednesday, but the medtech company beat Wall Street's fourth-quarter forecasts.

The tools ideate on Boston Scientific’s Farapulse PFA system, which contributed towards a 172% uptick in the company’s Q4 ...

Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

Boston Scientific announced won CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software.

So far, BSX stock has risen 19% year-to-date. Separately, CROX reports earnings tomorrow. Will the stock pop on the news? See ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Boston Scientific, with approximately 10,000 employees in Minnesota, reported a fourth-quarter adjusted net profit of $1 ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Argus Research analyst David Toung maintained a Buy rating on Boston Scientific (BSX – Research Report) on February 14. The company’s shares ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...